BIOATLA INC (BCAB) Stock News
NASDAQ:BCAB - Nasdaq - US09077B1044 - Common Stock - Currency: USD
BCAB Latest News, Press Relases and Analysis
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions...
BioAtla to Participate in the Citizens Life Sciences Conference
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024
BCAB stock results show that BioAtla met analyst estimates for earnings per share the second quarter of 2024.
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioAtla (NASDAQ:BCAB) just reported results for the first quarter of 2024.BioAt...
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026...
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the first quarter of 2024.
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioAtla (NASDAQ:BCAB) just reported results for the fourth quarter of 2023.BioA...
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”)...
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the fourth quarter of 2023.
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS...
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Mentions: CNTX
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin...
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients...
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout...